Albertsons Companies, Inc. - 10-Q Summary (Q1 Fiscal 2026)
Business Context and Reporting Period
This report covers the 16-week period ended June 20, 2026 (First Quarter of Fiscal 2026). Albertsons Companies, Inc. operates approximately 2,240 stores across 35 states and the District of Columbia under banners including Albertsons, Safeway, and Jewel-Osco. The company serves approximately 36.5 million customers weekly and employs roughly 275,000 associates. During the quarter, the company announced "ACI Edge," an operating structure realignment consolidating 11 divisions into four regions to improve efficiency and accountability.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales and Other Revenue | $24,941.6 million | $24,880.8 million |
| Gross Margin | $6,638.1 million (26.6%) | $6,738.3 million (27.1%) |
| Operating Income | $263.6 million | $449.3 million |
| Net Income | $84.7 million ($0.17/share) | $236.4 million ($0.41/share) |
| Adjusted Net Income | $210.3 million ($0.42/share) | $318.9 million ($0.55/share) |
| Adjusted EBITDA | $1,013.2 million | $1,111.0 million |
| Operating Cash Flow | $728.9 million | $754.4 million |
| Total Debt (Carrying Value) | $9,162.8 million | $8,946.6 million |
| Cash and Cash Equivalents | $293.4 million | $198.6 million |
Material Changes vs. Prior Period
- Revenue: Net sales increased 0.2% year-over-year, driven primarily by higher fuel sales. However, identical sales (excluding fuel) declined 0.8%.
- Profitability: Net income decreased significantly by 64% to $84.7 million. This decline was driven by lower identical sales, increased selling and administrative expenses (up 42 basis points excluding fuel), and higher interest expense ($166.7 million vs. $141.8 million).
- Margins: Gross margin rate decreased 50 basis points to 26.6%, impacted by higher delivery/handling costs from digital growth and fuel costs, partially offset by pharmacy margin improvements.
- Debt: Total debt increased by approximately $216 million, primarily due to higher utilization of the Asset-Based Loan (ABL) facility ($700 million outstanding vs. $425 million previously).
- Shareholder Returns: The company increased its quarterly dividend to $0.17 per share and repurchased 13.4 million shares for $226.5 million.
Outlook, Risks, and Unusual Items
- Legal Contingencies (Opioid Settlement): The company reached a settlement framework for opioid-related claims involving remediation payments of up to $655.1 million to states and $21.7 million to tribes, plus $97.0 million in legal fees. A loss of $773.8 million was recorded in the prior fiscal year; payments are expected over nine years. The State of Washington is not included in this framework.
- Merger Litigation: Following the termination of the merger with Kroger due to regulatory injunctions, Albertsons is suing Kroger for breach of contract, seeking damages in addition to a $600 million termination fee. Trial is scheduled for October 2026.
- False Claims Act: Two qui tam actions regarding pharmacy pricing remain pending. The company prevailed at trial in one case (Schutte), which is currently on appeal.
- Outlook: Management expects to continue investing in digital capabilities, AI, and customer value propositions. Liquidity needs for the next 12 months are estimated between $6.0 billion and $6.7 billion.
Investor Verification Checklist
- Opioid Settlement Finalization: Verify the status of the "Opioid Settlement Framework" and whether participation levels are sufficient to make the agreement effective, as actual losses could differ materially from estimates.
- Kroger Litigation Outcome: Monitor the progress of the lawsuit against Kroger regarding the terminated merger, specifically the potential recovery of the $600 million termination fee and additional damages.
- Identical Sales Trends: Assess whether the 0.8% decline in identical sales (excluding fuel) stabilizes given the company's focus on value-conscious consumers and digital growth.
- ABL Facility Utilization: Review the $700 million outstanding balance on the ABL facility and the company's ability to manage liquidity needs within the projected $6.0–$6.7 billion range.
- Pharmacy Margin Pressure: Evaluate the impact of the Inflation Reduction Act (IRA) on pharmacy sales growth and margins, which management cites as a headwind.